Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial.

ABSTRACT:

Introduction

Previous studies of long-term treatment response in fibromyalgia and other chronic pain states have generally been limited to approximately one year, leaving questions about the longer-term durability of response. The purpose of this study was to demonstrate continuing efficacy of milnacipran by characterizing changes in pain and other fibromyalgia symptoms after discontinuing long-term treatment. The mean length of milnacipran treatment at the time of randomized withdrawal was 36.1 months from initial exposure to milnacipran (range, 17.9 to 54.4 months).

Methods

After completing a long-term, open-label, lead-in study of milnacipran (which followed varying periods of exposure in previous studies), adult patients with fibromyalgia entered the four-week open-label

SUBMITTER: Clauw DJ 

PROVIDER: S-EPMC3978750 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature